Get the Stockscreener App
780.19
0.56%
-4.42
Regeneron Pharmaceuticals Inc stock is traded at $780.19, with a volume of 618.33K.
It is down -0.56% in the last 24 hours and up +19.21% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$784.61
Open:
$784.7
24h Volume:
618.33K
Relative Volume:
0.58
Market Cap:
$80.58B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
18.68
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
+3.21%
1M Performance:
+19.21%
6M Performance:
+31.82%
1Y Performance:
+3.35%
1-Day Range:
$779.50
$788.98
1-Week Range:
$756.64
$790.98
52-Week Range:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Choreo LLC Acquires 1,224 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Earnings Beat: What is the fair value of Regeneron Pharmaceuticals Inc. stock nowJuly 2025 Catalysts & Short-Term Swing Trade Alerts - moha.gov.vn
Advisors Asset Management Inc. Cuts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Will EU Approval of Dupixent for CSU Transform Regeneron Pharmaceuticals' (REGN) Long-Term Growth Narrative? - simplywall.st
Regeneron Claims Biocon Drug Mimics Its Patented Medicine - Law360
Te Ahumairangi Investment Management Ltd Acquires 4,278 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Russell Investments Group Ltd. Has $91.14 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500? - Barchart.com
Magnetar Financial LLC Has $247,000 Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Codex Capital Asset Management L.L.C. Trims Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients - Yahoo Finance UK
Atopic Dermatitis Drugs Market to Reach $29.43 Billion by 2032, Driven by Rising Disease Prevalence & Strong Therapeutic Innovation | SNS Insider - GlobeNewswire Inc.
Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Is Regeneron’s Stock Price Surge Justified After Recent FDA Approvals? - simplywall.st
Rhenman & Partners Asset Management AB Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by Hsbc Global Res to Strong-Buy Rating - MarketBeat
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 - Seeking Alpha
North Star Asset Management Inc. Buys Shares of 737 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Elo Mutual Pension Insurance Co Has $5.73 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals Stock Jumped 60%? - Trefis
XTX Topco Ltd Acquires 11,667 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Oak Associates Ltd. OH Has $4.30 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Prudential Financial Inc. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Evoq launches FDA-registered dark adaptation testing device for IRDs - Eyes On Eyecare
Regeneron Pharmaceuticals (REGN): Examining Valuation After Recent Share Price Momentum - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Truist Financial - MarketBeat
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $770.00 at Scotiabank - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Buy Rating from Analysts at HSBC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mediolanum International Funds Ltd - MarketBeat
Rhumbline Advisers Sells 2,508 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cetera Investment Advisers - MarketBeat
DCF Advisers LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Charles Schwab Investment Management Inc. Has $378.14 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
EU approves Sanofi and Regeneron’s Dupixent as first targeted therapy for chronic spontaneous urticaria - Seeking Alpha
Inside Regeneron’s 3-Million-Sample Bet On Collaborative Genomics - Citeline News & Insights
Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria - MarketScreener
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria - The Manila Times
Regeneron and Sanofi Announce European Commission Approval of Dupixent for Moderate-to-Severe Chronic Spontaneous Urticaria - Quiver Quantitative
Regeneron (NASDAQ: REGN) gets EU OK for Dupixent as first CSU therapy in over a decade - Stock Titan
FDA approves new EYLEA HD indication, expanded dosing intervals - Eyes On Eyecare
Truist Securities Lowers Price Target for Regeneron Pharmaceuticals (REGN) to $798 | REGN Stock News - GuruFocus
HSBC Initiates Buy Rating on Regeneron (REGN) with $890 Target - GuruFocus
Regeneron, Bayer Lose Eye Med Biosimilar Battle - Law360
Regeneron a new buy at HSBC on Eylea HD uptake, cancer therapy catalysts (REGN:NASDAQ) - Seeking Alpha
Scotiabank Raises Price Target for Regeneron Pharmaceuticals (RE - GuruFocus
1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month - Finviz
Mufg Securities Americas Inc. Has $1.21 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Truist Securities assumes coverage on Regeneron stock with Buy rating - Investing.com
HSBC Initiates Coverage on Regeneron Pharmaceuticals (REGN) with a 'Buy' Rating | REGN Stock News - GuruFocus
HSBC Initiates Regeneron Pharmaceuticals at Buy With $890 Price Target - MarketScreener
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.37%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):